FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2136139557> ?p ?o ?g. }

• W2136139557 endingPage "884" @default.
• W2136139557 startingPage "875" @default.
• W2136139557 abstract "Background Cervical dystonia is managed mainly by repeated botulinum toxin injections. We aimed to establish whether pallidal neurostimulation could improve symptoms in patients not adequately responding to chemodenervation or oral drug treatment. Methods In this randomised, sham-controlled trial, we recruited patients with cervical dystonia from centres in Germany, Norway, and Austria. Eligible patients (ie, those aged 18–75 years, disease duration ≥3 years, Toronto Western Spasmodic Torticollis Rating Scale [TWSTRS] severity score ≥15 points) were randomly assigned (1:1) to receive active neurostimulation (frequency 180 Hz; pulse width 120 μs; amplitude 0·5 V below adverse event threshold) or sham stimulation (amplitude 0 V) by computer-generated randomisation lists with randomly permuted block lengths stratified by centre. All patients, masked to treatment assignment, were implanted with a deep brain stimulation device and received their assigned treatment for 3 months. Neurostimulation was activated in the sham group at 3 months and outcomes were reassessed in all patients after 6 months of active treatment. Treating physicians were not masked. The primary endpoint was the change in the TWSTRS severity score from baseline to 3 months, assessed by two masked dystonia experts using standardised videos, analysed by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00148889. Findings Between Jan 19, 2006, and May 29, 2008, we recruited 62 patients, of whom 32 were randomly assigned to neurostimulation and 30 to sham stimulation. Outcome data were recorded in 60 (97%) patients at 3 months and 56 (90%) patients at 6 months. At 3 months, the reduction in dystonia severity was significantly greater with neurostimulation (–5·1 points [SD 5·1], 95% CI −7·0 to −3·5) than with sham stimulation (−1·3 [2·4], −2·2 to −0·4, p=0·0024; mean between-group difference 3·8 points, 1·8 to 5·8) in the intention-to-treat population. Over the course of the study, 21 adverse events (five serious) were reported in 11 (34%) of 32 patients in the neurostimulation group compared with 20 (11 serious) in nine (30%) of 30 patients in the sham-stimulation group. Serious adverse events were typically related to the implant procedure or the implanted device, and 11 of 16 resolved without sequelae. Dysarthria (in four patients assigned to neurostimulation vs three patients assigned to sham stimulation), involuntary movements (ie, dyskinesia or worsening of dystonia; five vs one), and depression (one vs two) were the most common non-serious adverse events reported during the course of the study. Interpretation Pallidal neurostimulation for 3 months is more effective than sham stimulation at reducing symptoms of cervical dystonia. Extended follow-up is needed to ascertain the magnitude and stability of chronic neurostimulation effects before this treatment can be recommended as routine for patients who are not responding to conventional medical therapy. Funding Medtronic. Cervical dystonia is managed mainly by repeated botulinum toxin injections. We aimed to establish whether pallidal neurostimulation could improve symptoms in patients not adequately responding to chemodenervation or oral drug treatment. In this randomised, sham-controlled trial, we recruited patients with cervical dystonia from centres in Germany, Norway, and Austria. Eligible patients (ie, those aged 18–75 years, disease duration ≥3 years, Toronto Western Spasmodic Torticollis Rating Scale [TWSTRS] severity score ≥15 points) were randomly assigned (1:1) to receive active neurostimulation (frequency 180 Hz; pulse width 120 μs; amplitude 0·5 V below adverse event threshold) or sham stimulation (amplitude 0 V) by computer-generated randomisation lists with randomly permuted block lengths stratified by centre. All patients, masked to treatment assignment, were implanted with a deep brain stimulation device and received their assigned treatment for 3 months. Neurostimulation was activated in the sham group at 3 months and outcomes were reassessed in all patients after 6 months of active treatment. Treating physicians were not masked. The primary endpoint was the change in the TWSTRS severity score from baseline to 3 months, assessed by two masked dystonia experts using standardised videos, analysed by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00148889. Between Jan 19, 2006, and May 29, 2008, we recruited 62 patients, of whom 32 were randomly assigned to neurostimulation and 30 to sham stimulation. Outcome data were recorded in 60 (97%) patients at 3 months and 56 (90%) patients at 6 months. At 3 months, the reduction in dystonia severity was significantly greater with neurostimulation (–5·1 points [SD 5·1], 95% CI −7·0 to −3·5) than with sham stimulation (−1·3 [2·4], −2·2 to −0·4, p=0·0024; mean between-group difference 3·8 points, 1·8 to 5·8) in the intention-to-treat population. Over the course of the study, 21 adverse events (five serious) were reported in 11 (34%) of 32 patients in the neurostimulation group compared with 20 (11 serious) in nine (30%) of 30 patients in the sham-stimulation group. Serious adverse events were typically related to the implant procedure or the implanted device, and 11 of 16 resolved without sequelae. Dysarthria (in four patients assigned to neurostimulation vs three patients assigned to sham stimulation), involuntary movements (ie, dyskinesia or worsening of dystonia; five vs one), and depression (one vs two) were the most common non-serious adverse events reported during the course of the study. Pallidal neurostimulation for 3 months is more effective than sham stimulation at reducing symptoms of cervical dystonia. Extended follow-up is needed to ascertain the magnitude and stability of chronic neurostimulation effects before this treatment can be recommended as routine for patients who are not responding to conventional medical therapy." @default.
• W2136139557 created "2016-06-24" @default.
• W2136139557 creator A5002340019 @default.
• W2136139557 creator A5013035262 @default.
• W2136139557 creator A5015932829 @default.
• W2136139557 creator A5016423019 @default.
• W2136139557 creator A5021241375 @default.
• W2136139557 creator A5031810199 @default.
• W2136139557 creator A5032593493 @default.
• W2136139557 creator A5032861326 @default.
• W2136139557 creator A5034219333 @default.
• W2136139557 creator A5035575290 @default.
• W2136139557 creator A5037338326 @default.
• W2136139557 creator A5040286592 @default.
• W2136139557 creator A5044208679 @default.
• W2136139557 creator A5044899932 @default.
• W2136139557 creator A5047447270 @default.
• W2136139557 creator A5049406744 @default.
• W2136139557 creator A5054212834 @default.
• W2136139557 creator A5054677591 @default.
• W2136139557 creator A5065382543 @default.
• W2136139557 creator A5065746961 @default.
• W2136139557 creator A5067734578 @default.
• W2136139557 creator A5070416480 @default.
• W2136139557 creator A5070448462 @default.
• W2136139557 creator A5071626950 @default.
• W2136139557 creator A5074139715 @default.
• W2136139557 creator A5074475092 @default.
• W2136139557 creator A5074559947 @default.
• W2136139557 creator A5077625777 @default.
• W2136139557 creator A5079864110 @default.
• W2136139557 creator A5080411240 @default.
• W2136139557 creator A5083610914 @default.
• W2136139557 creator A5083855931 @default.
• W2136139557 creator A5085574398 @default.
• W2136139557 date "2014-09-01" @default.
• W2136139557 modified "2023-10-18" @default.
• W2136139557 title "Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial" @default.
• W2136139557 cites W1779254138 @default.
• W2136139557 cites W1867291225 @default.
• W2136139557 cites W1942858747 @default.
• W2136139557 cites W1970151008 @default.
• W2136139557 cites W1976545284 @default.
• W2136139557 cites W1984242967 @default.
• W2136139557 cites W1990410007 @default.
• W2136139557 cites W2001591294 @default.
• W2136139557 cites W2005498968 @default.
• W2136139557 cites W2007776037 @default.
• W2136139557 cites W2008123743 @default.
• W2136139557 cites W2019941448 @default.
• W2136139557 cites W2021575173 @default.
• W2136139557 cites W2027142476 @default.
• W2136139557 cites W2030727295 @default.
• W2136139557 cites W2034285593 @default.
• W2136139557 cites W2041462105 @default.
• W2136139557 cites W2065085991 @default.
• W2136139557 cites W2069713889 @default.
• W2136139557 cites W2070647840 @default.
• W2136139557 cites W2079846837 @default.
• W2136139557 cites W2088037244 @default.
• W2136139557 cites W2091046222 @default.
• W2136139557 cites W2093537722 @default.
• W2136139557 cites W2101801005 @default.
• W2136139557 cites W2107125573 @default.
• W2136139557 cites W2110255132 @default.
• W2136139557 cites W2117967389 @default.
• W2136139557 cites W2131134103 @default.
• W2136139557 cites W2145092686 @default.
• W2136139557 cites W2151916085 @default.
• W2136139557 cites W2159518696 @default.
• W2136139557 cites W2162700884 @default.
• W2136139557 cites W2333735581 @default.
• W2136139557 cites W2795831496 @default.
• W2136139557 cites W4251743304 @default.
• W2136139557 doi "https://doi.org/10.1016/s1474-4422(14)70143-7" @default.
• W2136139557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25127231" @default.
• W2136139557 hasPublicationYear "2014" @default.
• W2136139557 type Work @default.
• W2136139557 sameAs 2136139557 @default.
• W2136139557 citedByCount "254" @default.
• W2136139557 countsByYear W21361395572014 @default.
• W2136139557 countsByYear W21361395572015 @default.
• W2136139557 countsByYear W21361395572016 @default.
• W2136139557 countsByYear W21361395572017 @default.
• W2136139557 countsByYear W21361395572018 @default.
• W2136139557 countsByYear W21361395572019 @default.
• W2136139557 countsByYear W21361395572020 @default.
• W2136139557 countsByYear W21361395572021 @default.
• W2136139557 countsByYear W21361395572022 @default.
• W2136139557 countsByYear W21361395572023 @default.
• W2136139557 crossrefType "journal-article" @default.
• W2136139557 hasAuthorship W2136139557A5002340019 @default.
• W2136139557 hasAuthorship W2136139557A5013035262 @default.
• W2136139557 hasAuthorship W2136139557A5015932829 @default.
• W2136139557 hasAuthorship W2136139557A5016423019 @default.
• W2136139557 hasAuthorship W2136139557A5021241375 @default.
• W2136139557 hasAuthorship W2136139557A5031810199 @default.
• W2136139557 hasAuthorship W2136139557A5032593493 @default.

• next